Human umbilical cord blood mononuclear cell transplantation for delayed encephalopathy after carbon monoxide intoxication

Dianrong Gong¹
Haiyan Yu¹
Weihua Wang²
Haixin Yang¹
Fabin Han¹,²

¹Department of Neurology, ²Centre for Stem Cells and Regenerative Medicine, Liaocheng People’s Hospital, The Affiliated Liaocheng Hospital, Taishan Medical University, Shandong, People’s Republic of China

Abstract: Stem cell transplantation is one of the potential treatments for neurological disorders. Since human umbilical cord stem cells have been shown to provide neuroprotection and promote neural regeneration, we have attempted to transplant the human umbilical cord blood mononuclear cells (hUCB-MNCs) to treat patients with delayed encephalopathy after carbon monoxide intoxication (DEACOI). The hUCB-MNCs were isolated from fresh umbilical cord blood and were given to patients subarachnoidally. Physical examinations, mini-mental state examination scores, and computed tomography scans were used to evaluate the improvement of symptoms, signs, and pathological changes of the patient’s brain before and after hUCB-MNC transplantation. A total of 12 patients with DEACOI were treated with hUCB-MNCs in this study. We found that most of the patients have shown significant improvements in movement, behavior, and cognitive function, and improved brain images in 1–4 months from the first transplantation of hUCB-MNCs. None of these patients have been observed to have any severe adverse effects. Our study suggests that the hUCB-MNC transplantation may be a safe and effective treatment for DEACOI. Further studies and clinical trials with more cases, using more systematic scoring methods, are needed to evaluate brain structural and functional improvements in patients with DEACOI after hUCB-MNC therapy.

Keywords: human umbilical cord blood mononuclear cells, transplantation, delayed encephalopathy after carbon monoxide intoxication, MMSE

Introduction
Carbon monoxide (CO) intoxication is one of the most severe lethal conditions for persons exposed to excess CO in industrial and living environments. Since the affinity of CO to hemoglobin is more than 250 times higher than that of oxygen, the formation of carboxyhemoglobin decreases the transport of blood oxygen to the tissues and causes reduced oxygen availability (hypoxia).¹ The common symptoms of acute CO intoxication are headache, nausea, vomiting, transient loss of consciousness, altered mental status, and deep coma. Most patients with acute CO intoxication can recover from the first week of the acute phase; however, around 1%–30% of patients develop delayed encephalopathy after CO intoxication (DEACOI) 2–4 weeks after recovery from the acute CO poisoning. The main clinical characteristics of DEACOI include neurological, cognitive, and psychological symptoms and signs. Pathologically, patients with DEACOI have several regions of brain lesions, which include the cortex, cerebellum, and substantial nigra.²⁻³ Brain lesions also occur in the white matter and basal ganglia. Even though hyperbaric oxygen is a useful treatment for the acute phase of CO intoxication, there are no effective treatments for patients with DEACOI.
One potential therapeutic approach is to use stem cells, through different transplantation methods, to repair and protect the damaged neurons and glial cells caused by DEACOI. Neural stem cells were proposed to be a useful cell-based therapy for neurological disease because of their ability to differentiate into functional neural cells; however, there are several issues such as the ethical concerns and immune rejection problems with the clinical application of the neural stem cells. The preclinical safety, efficacy, and ethical problems associated with neural stem cells need to be considered.

Human umbilical cord blood (hUCB) cells were reported to treat neurological disorders, as they have been shown to demonstrate neuroprotection, immunomodulation, and stimulation of neuroregeneration. Since hUCB cells are easily obtained and have the ability to differentiate into neurons, hUCB cell transplantation has been shown to be effective in animal models of neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease, and amyotrophic lateral sclerosis. A recent study indicated that the hUCB-derived mesenchymal stem cells can reduce the apoptosis of cultured hippocampal neurons induced by amyloid-β (Aβ), the toxic protein of Alzheimer’s disease. Furthermore, the hUCB mesenchymal stem cells were found to rescue learning and memory function in the Alzheimer’s disease mouse model. Other studies have also shown that hUCB cell transplantation is a safe and effective therapeutic approach for spinal cord injury and stroke. We investigated the safety and efficacy of hUCB mononuclear cells (hUCB-MNCs) transplantation to treat patients with DEACOI and evaluated the achieved beneficial effects.

**Materials and methods**

**Patients**

Originally, 14 patients with DEACOI were enrolled in this study, which was approved by the ethical committee of Liaocheng People’s Hospital, and each patient completed an informed consent form. The patients were diagnosed with DEACOI according to the criteria described in a previous publication. Each patient had been intoxicated by passively inhaling CO and then developed DEACOI 2–6 weeks after recovery from the acute phase. They had at least one of the following symptoms: cognitive and mental dysfunctions; extrapyramidal features such as the rigidity, dystonia, and resting tremor; other neurological signs including dysmetria and small step gait; urinary incontinence. All of the patients had been excluded for mental illness, dementia, and physical dysfunction. No patients had been observed to have any fever, headaches, back pain, or other adverse reactions in the first few days after treatment or thereafter during the follow-up study. We conducted 4–6 consecutive months of follow-up visits to study the safety and therapeutic efficacy of the hUCB-MNC transplantation in 12 patients (two were lost to follow-up).

**Isolation and preparation of hUCB stem cells**

The hUCB stem cells were collected immediately after the birth of newborns. All hUCB cell samples were collected in the same hospital (Liaocheng People’s Hospital) and were collected from both males and females, as the distinction does not affect the quality of the mononuclear cells. A volume of 100–150 mL of umbilical cord blood was collected from each healthy donor, and the hUCB-MNCs were isolated using SCR-200I extraction kit (Zhonglianda Biological Inc., Yingchuan, Ningxia, People’s Republic of China). It took approximately 3 hours from the time of umbilical cord blood collection to the mononuclear cell extraction, and it took less than 1 hour from the extraction to the time of transplantation. The transplantation procedure was carried out in a sterilized operating room. Approximately 1.0–2.0 × 10^6 hUCB-MNCs in a 3–4 mL suspension in phosphate buffered saline were injected by lumbar puncture into the patient’s subarachnoid space over a period of 2–3 minutes.

**Physical examination and mini-mental state examination scoring**

To evaluate the therapeutic efficacy of the hUCB-MNC transplantation, physical examinations were performed on all patients by two neurologists, and the mini-mental state examination (MMSE) scores were used to evaluate the recovery of cognitive and mental dysfunctions. No patients had been observed to have any fever, headaches, back pain, or other adverse reactions in the first few days after treatment or thereafter during the follow-up study. We conducted 4–6 consecutive months of follow-up visits to study the safety and therapeutic efficacy of the hUCB-MNC transplantation in 12 patients (two were lost to follow-up).

**CT image analysis**

In order to understand the recovery of the brain lesions after hUCB-MNC transplantation therapy, we used a computed tomography (CT) scan to examine the brain structure changes in these patients. The images were then viewed by CT technologists and neurologists to identify the abnormal changes in the brain. Brain slices appear gray on a CT scan, and any abnormalities are shown as darker or lighter areas in the brain and around tissues.

**Laboratory tests**

Before transplantation, the blood, urine, stool, biochemical parameters, tumor markers, and possibility for the presence of
virus and microorganism were examined for all 12 patients, and were examined for some of the patients after transplantation therapy.

**Statistical analysis**

SPSS statistical software (IBM Corporation, Armonk, NY, USA) was used to compare the cognitive improvement effects of hUCB-MNC transplantation among different treatment groups using analysis of variance (one-way ANOVA).

**Results**

In this study, we have investigated the safety and therapeutic effects of hUCB-MNC transplantation in patients with DEACOI. We treated 14 patients, but only 12 patients completed the 4-month follow-up visit. Their ages (mean ± standard deviation) were in the range of 42–72 years (59.7 ± 11.2). All patients had a history of CO poisoning coma with a coma time of 2–20 hours (9.3 ± 6.4) and a temporary asymptomatic period (pseudorecovery) of 6–30 days (17.3 ± 8.1) after the acute phase. All these patients received conventional hyperbaric oxygen therapy after acute CO intoxication onset, but the disease still progressed rapidly. The earliest symptom of patients with DEACOI is mental impairment. The other symptoms and signs of DEACOI include disturbance of consciousness, behavioral abnormalities, decorticate state, extrapyramidal symptoms, urinary incontinence, and increased muscle tension changes, which are summarized in Table 1.

To avoid the possible infections derived from the allogenic transplantation, the hUCB-MNCs were tested for quality control of the clinical applications after extraction from the hUCB. Each batch of cells was confirmed negative for endotoxin, hepatitis B, and mycoplasma, and only the qualified hUBC-MNCs were allowed to be transplanted to patients. All the patients were followed-up for up to 6 months after transplantation. Since some patients could not be followed for a consecutive 6 months, we had only 12 patients who completed the 4 months of follow-up study. No adverse effects or immunological rejections were noted after transplantation during the 4 months of study, with some patients having been observed for more than 6 months with no adverse effects noted. Since the clinical characteristics between the patients varied, we created three scales to evaluate the improvement after transplantation of the hUCB-MNCs so that we could perform the statistical analysis in this study. These three scales are as follows: complete recovery, which indicates that the patient has recovered to the normal status as they were before the CO intoxication; partial recovery, which indicates that the patient has recovered but still has some unconsciousness problems; and no response, which indicates that the patient did not have any observable improvements in clinical manifestations of DEACOI. We found that the effective rate of hUCB-MNC transplantation for DEACOI is 100%. Seven of the 12 patients completely recovered and five of the 12 patients are partially recovered. The overall therapeutic effects of hUCB-MNC transplantation in these 12 DEACOI patients are shown in Table 2.

In order to evaluate the improvements in cognitive and mental dysfunctions after hUCB-NMC transplantation, the MMSE was used to record the changes of the neurological and cognitive impairments. We used the following scale to assess the recovery of cognitive and mental conditions: scores on the MMSE range from 0–30, with scores of 25 or higher being traditionally considered normal. Scores less than 10 generally indicate severe impairment, while scores between 10–19 indicate moderate dementia. We evaluated the MMSE scores of the patients; the average MMSE scores of the 12 patients before transplantation and 1, 2, and 4 months after transplantation were 1.86, 6.93, 16.5, and 23.14, respectively. Statistical analysis showed that the MMSE scores of the patients were significantly increased at 1, 2, and 4 months after transplantation compared to the MMSE scores of the patients before transplantation. Moreover the MMSE scores of patients were significantly increased at the time of 1, 2, and 4 months after transplantation compared to each other as shown in Figure 1 ($F = 33.098$, $P < 0.01$).

To analyze the changes in the brains of the patients, we used CT scan imaging to record the changes of the brain lesions before transplantation, as well as 1, 2, and 4 months after hUCB-MNC transplantation. CT examination was performed on all 12 patients before the hUCB-MNC transplantation. Ten of the 12 patients had abnormal CT images, while two patients had normal brain CT images before transplantation. Abnormal changes as observed by CT scan included symmetric abnormally low signal intensities and diffused images in bilateral cerebral hemisphere subcortex, the limb of internal capsule, and basal ganglia in ten patients. As some patients declined to take the CT examination, only five patients were examined by CT after hUCB-MNC transplantation. As a result, 4 months after transplantation, the abnormal brain diffusion of the five patients had disappeared, as shown for one patient in Figure 2, suggesting the transplanted hUCB-MNC improved recovery of the injured brain regions in patients with DEACOI.
Discussion

Stem cell transplantation has been suggested to be a challenging therapeutic method for treating the neurological disorders, blood disorders, diabetes, and other diseases. Animal studies and some clinical trials have provided evidence of therapeutic effects of stem cells for neurodegenerative diseases. Because human embryonic stem cells and fetal brain-derived neural progenitor cells raise ethical concerns and are of limited source, other stem cells such as bone marrow stem cells and umbilical cord blood stem cells have been used in trials

| Table 1 The clinical characteristics of the patients with DeACoI before and after the hUCB-MNC transplantation |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Patient | Age (y)/sex | Coma time (h) | Pseudorecovery time (d) | Neurological features Before | 1 month after | 2 months after | 4 months after |
| 1 | 72/female | 10 | 14 | Unconsciousness, urine incontinence, decorticated state, extrapyramidal abnormality | None | None | None |
| 2 | 66/female | 5 | 6 | Unconsciousness, urine incontinence, decorticated state, extrapyramidal abnormality | Urine incontinence | None | None |
| 3 | 57/female | 9 | 26 | Unconsciousness, urine incontinence, decorticated state, extrapyramidal abnormality, pathologic reflection | Urine incontinence, pathologic reflection | Pathologic reflection | None |
| 4 | 71/male | 4 | 15 | Urine incontinence | None | None | None |
| 5 | 61/male | 20 | 15 | Unconsciousness, urine incontinence, decorticated state, extrapyramidal abnormality, pathologic reflection | Urine incontinence, pathologic reflection | None | Pathologic reflection |
| 6 | 49/male | 2 | 15 | Urine incontinence, psychological abnormality, extrapyramidal abnormality | Urine incontinence, psychological abnormality, extrapyramidal abnormality | None | None |
| 7 | 42/female | 15 | 30 | Unconsciousness, urine incontinence, decorticated state, extrapyramidal abnormality | None | None | None |
| 8 | 70/male | 10 | 18 | Urine incontinence, pathologic reflection, extrapyramidal abnormality | Urine incontinence, pathologic reflection, extrapyramidal abnormality | Pathologic reflection | Pathologic reflection |
| 9 | 43/male | 10 | 4 | Urine incontinence, pathologic reflection, extrapyramidal abnormality | Urine incontinence, pathologic reflection, extrapyramidal abnormality | Pathologic reflection | None |
| 10 | 60/female | 16 | 23 | Urine incontinence, pathologic reflection, extrapyramidal abnormality | Urine incontinence, pathologic reflection, extrapyramidal abnormality | Pathologic reflection, extrapyramidal abnormality | Pathologic reflection, extrapyramidal abnormality |
| 11 | 49/male | 20 | 19 | Psychological abnormality | Psychological abnormality | Psychological abnormality | None |
| 12 | 46/male | 10 | 45 | Urine incontinence, decorticated state, extrapyramidal abnormality, pathologic reflection | Urine incontinence, extrapyramidal abnormality, pathologic reflection | Extrapyramidal abnormality | None |

Abbreviations: d, days; DeACoI, delayed encephalopathy after carbon monoxide intoxication; h, hours; hUCB-MNC, human umbilical cord blood mononuclear cells; y, years.
Table 2 The therapeutic efficacy of the hUCB-MNC transplantation in 12 patients with DEACOI

<table>
<thead>
<tr>
<th>Cases</th>
<th>Complete recovery</th>
<th>Partial recovery</th>
<th>Nonresponse</th>
<th>Effective rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>12</td>
<td>7</td>
<td>5</td>
<td>0</td>
<td>100%</td>
</tr>
</tbody>
</table>

Abbreviations: DEACOI, delayed encephalopathy after carbon monoxide intoxication; hUCB-MNC, human umbilical cord blood mononuclear cells.

attempting to treat neurological disorders. Several progenitor populations were isolated from the cord blood of the newborns and were shown to be able to differentiate to neurons in vitro and in vivo studies. Recently, bone marrow menenchymal stem cells have been shown to be effective in treating the 6-hydroxydopamine-lesioned Parkinson’s rats. The systemic and local injection approaches were attempted in order to study the efficacy of the transplanted stem cells in animal models with neurological diseases. Intravenous administration was shown to be effective in preventing and treating stroke in the rat model after a middle cerebral artery occlusion, and it was also shown to increase the recovery of behavioral and neurological functions and rescue the neurons in the ischemic regions. Other studies showed that hUCB cells improved the special learning and memory ability of transgenic mice with Alzheimer’s disease. In this study, we have investigated the safety and feasibility of the transplantation therapy of allogeneic hUCB-MNCs for patients with DEACOI. We injected hUCB-MNCs into patients by lumbar puncture transplantation and found that a single transplantation of hUCB-MNCs significantly improved the recovery of the cognitive, memory behaviors, and improved brain CT scans of the patients in 1, 2, or 4 months of transplantation, suggesting that lumbar puncture transplantation is an effective approach to improve conditions in patients with DEACOI. We have treated 12 patients with DEACOI through lumbar puncture transplantation of the hUCB-MNCs and achieved beneficial efficacy; however, the therapeutic efficiency varies from patient to patient. We noticed that some patients’ mental dysfunctions recovered in the first week, whereas other patients’ symptoms recovered later than a month after transplantation. Because the total number of cells isolated from the fetal cord blood is different among the individual donors, the number of the transplanted cells is different from patient to patient at the range of 1–2 × 10⁶ hUCB-MNCs. It seems that after pseudorecovery of patients with CO intoxication, the earlier the patient underwent hUCB-MNC transplantation therapy, the better the therapeutic role of transplantation was, even though we did not perform statistical analysis because of the limited cases enrolled in this study. In order to determine the optimal efficacy of transplantation, we need to recruit more patients and follow their progress after transplantation therapy for a longer period of time – one or two years. At the same time, a number of DEACOI patients without hUCB-MNC transplantation, as a control group, should be followed to compare the therapeutic effects between the patients who have received transplants and those who have not undergone the treatment. We also need to consider the patient conditions individually, and set up the stem cell treatment plan by a panel of clinicians, research scientists, and administrators to achieve the best therapeutic effects. In this study, we did not observe any signs of immune rejection in any of the patients, even though no immunosuppressive agents were given before or after hUCB-MNC transplantation therapy. This is probably due to the immature antigenity of the allogeneic hUCB-MNC, which could not induce the immune response in recipients. However, some blood immune cells and antibodies collected from patients post-transplantation remain to be examined in order to provide additional supporting evidence that hUCB-MNC transplantation does not induce an immune rejection response.

The therapeutic mechanism of stem cell transplantation is not completely known. Rather than cell replacement, other possible mechanisms of cell transplantation were proposed to play the important role in stem cell therapy, such as the secreted growth factors that could increase the cell survival and immunomodulation. Some studies indicated that the
stem cells directly affected the cell survival and microglial survival.27,28 Other studies suggested that immunomodulation mechanisms may play the main role in improving neuroprotection of stem cells in treating stroke and neurodegenerative diseases.26,29

Since hUCB-MNCs mainly differentiate to mesodermal and endodermal cells, and have limited differentiation into neural cells, other stem cells are being studied for the treatment of the neurological diseases.30,31 The most challenging objective in stem cell clinical transplantation is to induce the production of pluripotent stem cells derived from the patient’s own somatic cells, such as the fibroblast cells and blood cells, where they are reprogrammed by stem cell factors such as octamer-binding transcription factor 4 (OCT4), sex determining region Y box 2 (SOX2), Kruppel-like factor 4 (KLF4), and c-Myc.32,33

Recent studies have generated human induced pluripotent stem cells from patients with neurological diseases.7,34,35 The patient-derived induced pluripotent stem cells have been efficiently differentiated to the dopamine neurons, motor neurons, and interneurons. Transplantation studies have shown the induced pluripotent stem cells-derived neurons survived and migrated to the host brain tissues and improved the locomotive and behavioral activities in animal models with neurodegenerative diseases, and thus provided evidence for the future perspective of stem cell therapy in neurological diseases.

Disclosure
The authors report no conflicts of interest in this work.

References